Skip to main content

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

Molecular Probes and Imaging Agents

Ribbon Icon
Tatjana Atanasijevic
Program Director
Division of Applied Science & Technology (Biomedical Imaging) Program Area: Molecular Probes and Imaging Agents
This program supports development and biomedical application of molecular probes and imaging agents across all imaging modalities for the visualization, characterization and quantification of normal biological and pathophysiological processes and anatomy in living organisms at the molecular, cellular and organ levels.

Emphasis

The emphasis is on engineering of targeting and responsive molecular probes of high sensitivity and specificity for PET and SPECT (radiotracers), MR (T1, T2, CEST, hyperpolarized agents), EPR, CT, optical (fluorescent and bioluminescent probes), ultrasound (microbubbles) and photoacoustic imaging.  The imaging agents may be based on nano- and micro-particles, liposomes, dendrimers, proteins, small organic and inorganic molecules etc., and detectable by one or more imaging modalities.  Imaging agent development through methodologies such as chemical synthesis, biological mutagenesis, microfabrication, etc., may be pursued with an intent of leading to in vivo biomedical application.

Outcome

The goal of this program is to generate robust molecular probes, imaging agents and platforms for biomedical application across all disease areas to facilitate diagnostics and improve understanding of disease state, progression, and therapeutic response.

Additional emphasis

This program also supports the development of other imaging agents, for example:

  • multimodal molecular probes (PET/MRI, PET/fluorescent, etc.)
  • imaging reporter genes and reporter gene/imaging probe duos
  • molecular probes as part of theranostic systems or biosensors
  • imaging agents for cell labelling and in vivo tracking
  • molecular probes for image-guided interventions

Note

The following related scientific areas are supported by other NIBIB programs:

Related News

Science Highlights
December 19, 2024

NIH has awarded more than $4 million in funds and support services to three diagnostic technology developers as part of RADx ® Tech’s Advanced Platforms for HIV Viral Load Monitoring program.

NIBIB in the News
December 2, 2024

A tiny, four-fingered “hand” folded from a single piece of DNA can pick up the virus that causes COVID-19 for highly sensitive rapid detection and can even block viral particles from entering cells to infect them, University of Illinois Urbana-Champaign researchers report. Source: University of Illinois Urbana-Champaign News Bureau

Science Highlights
July 22, 2024

Due to its high accuracy, lab-based PCR testing is the gold standard for infectious disease diagnostics. Yet PCR's availability is limited, especially in low-resource settings. New research suggests a new kind of test could be more streamlined without sacrificing performance.

Science Highlights
June 12, 2024

To date, nine medical device developers participating in the RADx® Tech Independent Test Assessment Program have received emergency use authorization for at-home and point-of care test products that simultaneously detect COVID-19 and flu A/B.

NIBIB in the News
June 11, 2024

Scientists at the University of North Carolina at Chapel Hill have created innovative soft robots equipped with electronic skins and artificial muscles, allowing them to sense their surroundings and adapt their movements in real-time. These features make soft sensory robots highly adaptable and useful for enhancing medical diagnostics and treatments.  Source: UNC Chapel Hill